Similarly, the EGFR inhibitor erlotinib reduced pathological neovascularization in an oxygen-induced retinopathy (OIR) mouse model by inhibiting ADAM17 and EGFR [35]. This evidence concerns the gene ADAM17 and retinal disorder.